[go: up one dir, main page]

MX2017001804A - Mioinositol y uno o mas probioticos y sus usos. - Google Patents

Mioinositol y uno o mas probioticos y sus usos.

Info

Publication number
MX2017001804A
MX2017001804A MX2017001804A MX2017001804A MX2017001804A MX 2017001804 A MX2017001804 A MX 2017001804A MX 2017001804 A MX2017001804 A MX 2017001804A MX 2017001804 A MX2017001804 A MX 2017001804A MX 2017001804 A MX2017001804 A MX 2017001804A
Authority
MX
Mexico
Prior art keywords
probiotics
myoinositol
subject
pregnancy
woman
Prior art date
Application number
MX2017001804A
Other languages
English (en)
Other versions
MX374421B (es
Inventor
Mace Catherine
Silva Zolezzi Irma
Malcolm Godfrey Keith
Newton Baker Philip
Seng CHONG Yap
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017001804A publication Critical patent/MX2017001804A/es
Publication of MX374421B publication Critical patent/MX374421B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición de nutrición materna que comprende mioinositol y probióticos. Una composición tal se ha diseñado específicamente para proporcionar una nutrición óptima para una mujer que desee la gestación, una mujer gestante y/o para una mujer en período de lactancia. La invención se refiere, además, al uso de una combinación de mioinositol y uno o más probióticos para usar para reducir al mínimo la acumulación excesiva de grasa en un sujeto gestante o en un sujeto que desee la gestación, y/o para tratar o prevenir la diabetes mellitus gestacional y afecciones que se asocian a esta en un sujeto gestante y/o su descendencia, en donde dicha combinación de mioinositol y uno o más probióticos se administra a dicho sujeto antes y/o durante la gestación y/o durante la lactancia.
MX2017001804A 2014-08-08 2015-08-06 Mioinositol y uno o más probióticos y sus usos. MX374421B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14180403 2014-08-08
EP14180399 2014-08-08
EP15170915 2015-06-05
PCT/EP2015/068196 WO2016020495A1 (en) 2014-08-08 2015-08-06 Myo-inositol and one or more probiotic and use thereof

Publications (2)

Publication Number Publication Date
MX2017001804A true MX2017001804A (es) 2017-04-27
MX374421B MX374421B (es) 2025-03-06

Family

ID=53836572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001804A MX374421B (es) 2014-08-08 2015-08-06 Mioinositol y uno o más probióticos y sus usos.

Country Status (7)

Country Link
EP (1) EP3177155B1 (es)
CN (2) CN116270762A (es)
BR (1) BR112017001807B1 (es)
CA (1) CA2953030C (es)
MX (1) MX374421B (es)
PH (1) PH12017500014A1 (es)
WO (1) WO2016020495A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017249660B2 (en) * 2016-04-14 2020-03-26 International N&H Denmark Aps Bifidobacteria for increasing lean body mass
BR112018070518A2 (pt) * 2016-04-14 2019-01-29 Dupont Nutrition Biosci Aps bactéria do gênero bifidobacterium, usos de uma bactéria do gênero bifidobacterium e método para reduzir a ingestão de alimentos, energia e/ou gordura
CN110831609A (zh) 2017-06-30 2020-02-21 N·V·努特里奇亚 用于预防代谢紊乱的合生素组合物
CN110831608A (zh) * 2017-06-30 2020-02-21 N·V·努特里奇亚 预防疾病的合生素组合物
IT201700104446A1 (it) * 2017-09-19 2019-03-19 Lo Li Pharma Srl Compositions, uses and methods for treatment of infertility and subfertility
JP7193469B2 (ja) * 2017-10-31 2022-12-20 森永乳業株式会社 筋肉増量用組成物
CN108872424A (zh) * 2018-04-16 2018-11-23 南京医科大学 十二烷酸和前列腺素e2组合作为巨大儿辅助诊断标志物及其应用
MY210247A (en) 2018-06-22 2025-09-04 Fonterra Cooperative Group Ltd Use of polar lipids to treat or prevent gestational diabetes mellitus
CN108813262A (zh) * 2018-07-02 2018-11-16 杭州相生相成科技有限公司 一种含dha藻油的复合益生菌固体饮料
WO2020039014A1 (en) * 2018-08-22 2020-02-27 Société des Produits Nestlé S.A. Composition comprising isomers of inositol and its use
CN115460934A (zh) * 2019-08-26 2022-12-09 雀巢产品有限公司 肌醇和早产的预防
MX2022002063A (es) * 2019-08-26 2022-03-17 Nestle Sa Mioinositol y la prevencion de pprom.
US20220296534A1 (en) * 2019-08-30 2022-09-22 Societe Des Produits Nestle S.A. Scyllo-inositol and b-cell mediated disorders
EP4034092A1 (en) * 2019-09-24 2022-08-03 Société des Produits Nestlé S.A. Scyllo-inositol and its use as insulin sensitizer
WO2021105353A1 (en) * 2019-11-29 2021-06-03 Société des Produits Nestlé S.A. Compositions and methods with a probiotic and a nutrient and/or mineral for the prevention or treatment of mastitis
WO2021259938A1 (en) * 2020-06-22 2021-12-30 Société des Produits Nestlé S.A. Compositions comprising myo-inositol and their use in the prevention of post partum haemorrhage (pph)
BR112023003263A2 (pt) 2020-09-04 2023-03-21 Nestle Sa Composições e métodos para fornecer benefícios de saúde a um animal
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
KR20250078928A (ko) * 2022-09-07 2025-06-04 에어젠 파마 엘티디. 사일로이노시톨과 플라본의 조합

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW282398B (es) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
ITRM20040505A1 (it) * 2004-10-15 2005-01-15 Cd Invest Liofilizzati di batteri lattici e bifidobatteri ad alta dispersibilita'.
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
EP2452575A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of age-tailored nutritional formula with probiotics
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
ITFI20110252A1 (it) * 2011-11-22 2013-05-23 Lo Li Pharma Srl Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo.

Also Published As

Publication number Publication date
CN116270762A (zh) 2023-06-23
PH12017500014A1 (en) 2017-05-15
EP3177155A1 (en) 2017-06-14
BR112017001807B1 (pt) 2021-11-03
EP3177155B1 (en) 2019-09-25
BR112017001807A2 (pt) 2017-11-21
CA2953030C (en) 2023-10-10
CN106794206A (zh) 2017-05-31
WO2016020495A1 (en) 2016-02-11
MX374421B (es) 2025-03-06
CA2953030A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
MX2017001804A (es) Mioinositol y uno o mas probioticos y sus usos.
MX2017001738A (es) Vitamina b2 para la diabetes gestacional.
Bourke et al. Prenatal antidepressant exposure: clinical and preclinical findings
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
CL2016002732A1 (es) Suplementación microbioma neonatal
BR112018068126A2 (pt) sistemas e métodos para a produção e liberação de pasta fluida gelada medicinal
CL2017001335A1 (es) Cápsulas blandas de calcifediol.
PH12017550030A1 (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX2016014913A (es) Dispositivo y formulacion para el tratamiento topico de dolor que afecta a la zona vulvar del organo genital humano femenino.
CR20170470A (es) Tratamiento de pacientes con diabetes mellitus tipo 2
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
MX2018006026A (es) Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
MX2016011994A (es) Administracion de vitamina b2 materna para la prevencion del aumento de la adiposidad, el sobrepeso o la obesidad en la descendencia.
Subgroup et al. Diagnosis and therapy guideline of preterm birth (2014)
MX2019015889A (es) Administracion de vitamina b6 materna para la prevencion del aumento de la adiposidad, el sobrepeso a la obesidad en la descendencia.
MX2016011801A (es) Crema de estradiol de dosis baja.
Cavalla Status migrainosus and tension type headache: 3 case reports
AR107869A1 (es) Composición para el uso en la profilaxis de la enfermedad alérgica
CN302191919S (zh) 医用x射线乳腺摄影系统
PH12016500915A1 (en) Maternal vitamin b12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers
TWD178768S (zh) 護腿

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SOCIETE DES PRODUITS NESTLE S.A.*

FG Grant or registration